How Hazen was paid
$26.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Pension | Other | Total |
|---|---|---|---|---|---|---|---|
| Samuel N. HazenChief Executive Officer | $1,577,815 | $8,474,543 | $8,514,090 | $5,416,732 | $1,934,400 | $539,026 | $26,456,606 |
| Michael A. MarksExecutive Vice President and Chief Financial Officer | $982,500 | $1,776,295 | $1,784,399 | $2,422,729 | $3,305,382 | $83,806 | $10,355,111 |
| Jon M. FosterExecutive Vice President and Chief Operating Officer | $1,043,375 | $1,903,173 | $1,911,848 | $2,558,549 | $3,422,029 | $153,812 | $10,992,786 |
| Michael R. McAleveyExecutive Vice President – Chief Legal and Administrative Officer | $1,012,688 | $1,268,782 | $1,274,603 | $1,986,638 | — | $167,624 | $5,710,335 |
| Michael S. Cuffe, M.D.Executive Vice President and Chief Clinical Officer | $974,834 | $1,268,782 | $1,274,603 | $1,918,606 | — | $267,372 | $5,704,197 |
What changed and why
- $26.5MCEO total compensation increased to $26,456,606 in 2025 from $23,799,137 in 2024.
- 195.78%Annual incentive awards under the 2025 PEP paid out at 195.78% of target based on EBITDA and quality metrics.
- 50%Long-term equity awards for executives consist of 50% time-based SARs and 50% performance share units.
- 94%Stockholders expressed substantial support for executive compensation with approximately 94% approval at the 2025 annual meeting.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.